Mass General Brigham Study Links Glipizide to 13% Higher Cardiovascular Risk in Type 2 Diabetes Patients
Key Insights
Mass General Brigham (search) researchers analyzed data from nearly 50,000 type 2 diabetes (search) patients and found glipizide associated with a 13% increase in cardiovascular risk compared to DPP-4 inhibitors (search).
The five-year study examined patients with moderate cardiovascular risk treated with different sulfonylureas or DPP-4 inhibitors (search) alongside metformin across 10 study sites nationwide.
Glipizide showed higher incidence of heart failure (search), related hospitalization and death, while glimepiride and glyburide demonstrated relatively smaller and less clear cardiovascular effects.
A comprehensive analysis of nearly 50,000 type 2 diabetes (search) patients has revealed that glipizide, the most widely used sulfonylurea in the United States, carries a significantly higher cardiovascular risk compared to dipeptidyl peptidase-4 (search) (DPP-4) inhibitors. The Mass General Brigham (search) study, published in JAMA Network Open, found a 13% increase in cardiovascular risk associated with glipizide treatment over a five-year period.
Study Design and Patient Population
Researchers from Mass General Brigham (search) emulated a target trial by analyzing electronic health records and insurance claims data from the BESTMED consortium. The cohort included 48,165 patients with type 2 diabetes (search) and moderate cardiovascular risk who received care at 10 different study sites across the country, including Brigham and Women's Hospital, as well as those covered by two different national health insurance plans.
The study examined patients treated with different sulfonylureas (glimepiride, glipizide, or glyburide) or DPP-4 inhibitors (search) in addition to metformin, a primary diabetes medication. All participants were followed for five-year risk of major adverse cardiovascular events.
Key Findings on Cardiovascular Risk
The analysis revealed distinct cardiovascular risk profiles among different sulfonylureas. Glipizide demonstrated the most concerning safety signal, with a 13% increase in cardiovascular risk when compared to DPP-4 inhibitors (search). The drug was specifically linked to higher incidence of heart failure (search), related hospitalization, and death.
In contrast, glimepiride and glyburide showed relatively smaller and less clear cardiovascular effects, suggesting important differences within the sulfonylurea class that have not been previously well-characterized in long-term clinical data.
Clinical Context and Implications
"Patients with type 2 diabetes (search) are at heightened risk of adverse cardiovascular incidents such as stroke and cardiac arrest," said corresponding author Alexander Turchin, MD, MS, of the Division of Endocrinology at Brigham and Women's Hospital. "While sulfonylureas are popular and affordable diabetes medications, there is a lack of long-term clinical data on how they affect cardiac health in comparison to more neutral alternatives like dipeptidyl peptidase 4 inhibitors."
The findings challenge the common clinical practice of treating all sulfonylureas as therapeutically equivalent options. "Our study underscores the importance of evaluating each drug in a particular pharmacological class on its own merits," Turchin emphasized.
Research Limitations and Future Directions
The authors acknowledge that further research is needed to uncover the underlying mechanisms responsible for the differential cardiovascular effects observed among sulfonylureas. The study's observational design, while comprehensive in scope, cannot establish definitive causal relationships between specific medications and cardiovascular outcomes.
The research was funded in part by the Patient-Centered Outcomes Research Institute and involved collaboration across multiple institutions to ensure broad geographic and demographic representation in the patient cohort.